A BRCA1 deficient-like signature is enriched in breast cancer brain
... Introduction: There is an unmet clinical need for biomarkers to identify breast cancer patients at an increased risk of developing brain metastases. The objective is to identify gene signatures and biological pathways associated with human epidermal growth factor receptor 2-positive (HER2+) brain me ...
... Introduction: There is an unmet clinical need for biomarkers to identify breast cancer patients at an increased risk of developing brain metastases. The objective is to identify gene signatures and biological pathways associated with human epidermal growth factor receptor 2-positive (HER2+) brain me ...
Loss of BRCA1 expression in sporadic male breast carcinoma
... BRCA1 in male breast cancer not been demonstrated [22, 23]. The results of this study show that marked loss of BRCA1 protein in male breast carcinomas is associated with increased cell proliferation (as evidenced by significantly higher Ki-67 immunoreactivity) and less favorable prognosis. These fi ...
... BRCA1 in male breast cancer not been demonstrated [22, 23]. The results of this study show that marked loss of BRCA1 protein in male breast carcinomas is associated with increased cell proliferation (as evidenced by significantly higher Ki-67 immunoreactivity) and less favorable prognosis. These fi ...
![arXiv:q-bio/0403018v2 [q-bio.GN] 4 May 2004](http://s1.studyres.com/store/data/012836624_1-fbaf750bef930f63f681c5f723d18383-300x300.png)
Patient Support Guide to Genetic Testing for Hereditary Breast Cancer
... for breast cancer. High risk can come from a change in DNA called a mutation. Sometimes a mutation is passed down from a parent. Breast cancer caused by a mutation passed down from a parent is called hereditary breast cancer. This type of breast cancer is not very common. Only 5% to 10% of all breas ...
... for breast cancer. High risk can come from a change in DNA called a mutation. Sometimes a mutation is passed down from a parent. Breast cancer caused by a mutation passed down from a parent is called hereditary breast cancer. This type of breast cancer is not very common. Only 5% to 10% of all breas ...
beginner`s guide to BRCA1 and BRCA2
... We have two copies of each gene – one copy is inherited from our mother and one from our father. We have approximately 20,000 genes, each with a specific function that helps our bodies grow and function normally. Some genes work to protect against cancer by correcting damage that can occur in the DN ...
... We have two copies of each gene – one copy is inherited from our mother and one from our father. We have approximately 20,000 genes, each with a specific function that helps our bodies grow and function normally. Some genes work to protect against cancer by correcting damage that can occur in the DN ...
The five-year relative survival rate is now 98 % for women Breast
... The five-year relative survival rate is now 98 % for women with localized breast cancer.4 Almost $14 billion is spent in the United States each year on breast cancer treatment.3 ...
... The five-year relative survival rate is now 98 % for women with localized breast cancer.4 Almost $14 billion is spent in the United States each year on breast cancer treatment.3 ...
Aug 2014 - kConFab
... I wish to highlight the updates about the new breast cancer related genes that have been found by our national researchers. In our last edition we updated you about families that carry a particular ATM gene fault (mutation) and these families have all been sent a kConFab mutation notification letter ...
... I wish to highlight the updates about the new breast cancer related genes that have been found by our national researchers. In our last edition we updated you about families that carry a particular ATM gene fault (mutation) and these families have all been sent a kConFab mutation notification letter ...
Breast MRI for Women With Hereditary Cancer Risk
... (prevalent) cancer screen. All incident cancers were in situ or stage I lesions. These findings are the most encouraging yet reported for MRI screening. A second question is the relative value and timing of MRI screening vis-à-vis mammograms and, possibly, screening ultrasound. MRI and conventional ...
... (prevalent) cancer screen. All incident cancers were in situ or stage I lesions. These findings are the most encouraging yet reported for MRI screening. A second question is the relative value and timing of MRI screening vis-à-vis mammograms and, possibly, screening ultrasound. MRI and conventional ...
Contralateral Breast Cancer in BRCA1 and BRCA2 Mutation Carriers
... and to identify host- and treatment-related factors that might modify the risk. ...
... and to identify host- and treatment-related factors that might modify the risk. ...
Yale School Of Medicine
... genetics is that it can come from either side of the family. Those 5% or 10% of families in which breast cancer seems to be genetic, we have identified two genes that account for about half of those families and those genes are called BRCA1 and BRCA2. It stands for breast cancer gene 1 and breast ca ...
... genetics is that it can come from either side of the family. Those 5% or 10% of families in which breast cancer seems to be genetic, we have identified two genes that account for about half of those families and those genes are called BRCA1 and BRCA2. It stands for breast cancer gene 1 and breast ca ...
Comprehensive Cancer Panel
... What genes are covered by the Comprehensive Cancer Panel and what are the associated cancer risks? The Comprehensive Cancer Panel at GeneDx includes analysis of 32 genes associated with a hereditary predisposition to breast, ovarian, colorectal, endometrial, pancreatic, and other various cancers. T ...
... What genes are covered by the Comprehensive Cancer Panel and what are the associated cancer risks? The Comprehensive Cancer Panel at GeneDx includes analysis of 32 genes associated with a hereditary predisposition to breast, ovarian, colorectal, endometrial, pancreatic, and other various cancers. T ...
Implementing a K-RAS mutation testing service for colorectal cancer
... type but our assay detected a mutation. 1 non-concordant sample was re-cut and re-extracted then retested at RSCH and the lab in question. Both results agreed with our original results, showing a mutation. The other remains unresolved, however may be due to a sensitivity issue as it was original ...
... type but our assay detected a mutation. 1 non-concordant sample was re-cut and re-extracted then retested at RSCH and the lab in question. Both results agreed with our original results, showing a mutation. The other remains unresolved, however may be due to a sensitivity issue as it was original ...
BRCA2
BRCA2 and BRCA2 (/ˌbrækəˈtuː/) are a human gene and its protein product, respectively. The official symbol (BRCA2, italic for the gene, nonitalic for the protein) and the official name (breast cancer 2, early onset) are maintained by the HGNC. Orthologs, styled Brca2 and Brca2, are common in other mammal species. BRCA2 is a human tumor suppressor gene (specifically, a caretaker gene), found in all humans; its protein, also called by the synonym breast cancer type 2 susceptibility protein, is responsible for repairing DNA.BRCA2 and BRCA1 are normally expressed in the cells of breast and other tissue, where they help repair damaged DNA or destroy cells if DNA cannot be repaired. They are involved in the repair of chromosomal damage with an important role in the error-free repair of DNA double strand breaks. If BRCA1 or BRCA2 itself is damaged by a BRCA mutation, damaged DNA is not repaired properly, and this increases the risk for breast cancer. Thus, although the terms ""breast cancer susceptibility gene"" and ""breast cancer susceptibility protein"" (used frequently both in and outside the medical literature) sound as if they describe a proto-oncogene or oncogene, BRCA1 and BRCA2 are ""normal""; it is their mutation that is abnormal.The BRCA2 gene is located on the long (q) arm of chromosome 13 at position 12.3 (13q12.3). The human reference BRCA 2 gene contains 28 exons, and the cDNA has 10,254 base pairs coding for a protein of 3418 amino acids.The gene was first cloned by scientists at Myriad Genetics, Endo Recherche, Inc., HSC Research & Development Limited Partnership, and the University of Pennsylvania.Methods to diagnose the likelihood of a patient with mutations in BRCA1 and BRCA2 getting cancer were covered by patents owned or controlled by Myriad Genetics. Myriad's business model of exclusively offering the diagnostic test led from Myriad being a startup in 1994 to being a publicly traded company with 1200 employees and about $500M in annual revenue in 2012; it also led to controversy over high prices and the inability to get second opinions from other diagnostic labs, which in turn led to the landmark Association for Molecular Pathology v. Myriad Genetics lawsuit.